Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Drugs Made In America Acquisition II (DMII): which funds own it

SPAC / vehículos(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow DMII for free
Share

Sections with a free account

No concentrated manager holds it.

Who owns Drugs Made In America Acquisition II?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Drugs Made In America Acquisition II (13D filed Oct 2, 2025). As of Jun 30, 2026, the largest holders reported on Form 13F were Karpus Management (2.8 million shares), MMCAP International Inc. SPC (2.7 million shares) and Magnetar Financial (2.7 million shares).

Which institutions hold the most Drugs Made In America Acquisition II shares?

Per Form 13F filings as of Jun 30, 2026:

  1. 1. Karpus Management: 2.8 million shares
  2. 2. MMCAP International Inc. SPC: 2.7 million shares
  3. 3. Magnetar Financial: 2.7 million shares
  4. 4. Glazer Capital: 2.3 million shares
  5. 5. Highbridge Capital Management: 2.2 million shares
  6. 6. Millennium Management: 2.0 million shares
  7. 7. Hudson Bay Capital Management: 2.0 million shares
  8. 8. Wolverine Asset Management: 1.9 million shares
  9. 9. Polar Asset Management Partners: 1.5 million shares
  10. 10. Tenor Capital Management: 1.5 million shares

Sources:13D by Drugs Made In America Acquisition II (Oct 2, 2025) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
—
All 13F: 70
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$10.06
+0.9% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Concentrated managers holding it

None in the latest quarter.

Largest holders of DMII (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
—
Growth
Revenue (TTM)
—
Revenue growth
—
Net income (TTM)
$13.0M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
—
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Earnings quality and debt

104.9% of net income does not come from operations.

Operating cash flow ÷ net income (12 months)
-0.10
Interest coverage (operating income ÷ interest)
no data
Debt due within 12 months
$450K2.57 times cash and investments

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
no data
Amount (6 m)
no data
CEO/CFO bought (12 m)
No

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Drugs Made In America Acquisition II10.2%13Dfiling ↗Event: Oct 1, 2025 · filed: Oct 2, 2025

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Mar 6, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Nov 18, 2025Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Follow DMII for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow DMII